Athina Ifantidou

G. Gennimatas General Hospital

Eth. Aminis 41

Thessaloniki, 54635

Greece

SCHOLARLY PAPERS

3

DOWNLOADS
Rank 39,362

SSRN RANKINGS

Top 39,362

in Total Papers Downloads

1,774

SSRN CITATIONS

1

CROSSREF CITATIONS

0

Scholarly Papers (3)

Actions:
Email selected abstracts
1.

Immunogenicity after the First Dose of the BNT162b2 mRNA COVID-19 Vaccine: Real-World Evidence from Greek Healthcare Workers

Number of pages: 10 Posted: 19 Feb 2021
Konstantina Kontopoulou, Alexandra Ainatzoglou, Athina Ifantidou, Christos Nakas, Georgia Goudi, Eleni Antoniadou, Vasilios Adamopoulos, Nikitas Papadopoulos and Georgios Papazisis
G. Gennimatas General Hospital, Aristotle University of Thessaloniki - Department of Clinical Pharmacology, G. Gennimatas General Hospital, University of Bern - University Institute of Clinical Chemistry, G. Gennimatas General Hospital, G. Gennimatas General Hospital, G. Gennimatas General Hospital, G. Gennimatas General Hospital and Aristotle University of Thessaloniki - Department of Clinical Pharmacology
Downloads 1,249 (23,749)
Citation 2

Abstract:

Loading...

vaccine, BNT162b2, SARS-CoV-2, immunogenicity, healthcare workers, Greece, reactogenicity

2.

Second Dose of the BNT162b2 mRNA Vaccine in Greece: The Value of Timely Administration

Number of pages: 8 Posted: 01 Apr 2021
Konstantina Kontopoulou, Alexandra Ainatzoglou, Christos Nakas, Athina Ifantidou, Georgia Goudi, Eleni Antoniadou, Vasilios Adamopoulos, Nikitas Papadopoulos and Georgios Papazisis
G. Gennimatas General Hospital, Aristotle University of Thessaloniki - Department of Clinical Pharmacology, University of Bern - University Institute of Clinical Chemistry, G. Gennimatas General Hospital, G. Gennimatas General Hospital, G. Gennimatas General Hospital, G. Gennimatas General Hospital, G. Gennimatas General Hospital and Aristotle University of Thessaloniki - Department of Clinical Pharmacology
Downloads 293 (148,464)

Abstract:

Loading...

BNT162b2 mRNA vaccine, immunogenicity, seropositive, Greece

3.

Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Elderly People Over 85 Years of Age in Greece

Number of pages: 10 Posted: 11 Jun 2021
Konstantina Kontopoulou, Christos Nakas, Alexandra Ainatzoglou, Athina Ifantidou, Georgia Goudi, Paschalina Ntotsi, Antonis Baxevanidis, Matina Tsormpatzoglou, Chrysoula Belai, Christos Katsioulis and Georgios Papazisis
G. Gennimatas General Hospital, University of Bern - University Institute of Clinical Chemistry, Aristotle University of Thessaloniki - Department of Clinical Pharmacology, G. Gennimatas General Hospital, G. Gennimatas General Hospital, G. Gennimatas General Hospital, G. Gennimatas General Hospital, affiliation not provided to SSRN, G. Gennimatas General Hospital, G. Gennimatas General Hospital and Aristotle University of Thessaloniki - Department of Clinical Pharmacology
Downloads 232 (187,068)
Citation 1

Abstract:

Loading...

BNT162b2 mRNA COVID-19 vaccine, immunogenicity, SARS-CoV-2, elderly over age 85, Greece